What is B. Riley’s Estimate for Abacus Life Q1 Earnings?

Abacus Life, Inc. (NASDAQ:ABL) – Research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Abacus Life in a report issued on Monday, November 25th. B. Riley analyst M. Howlett anticipates that the company will post earnings per share of $0.25 for the quarter. B. Riley has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Abacus Life’s current full-year earnings is $0.64 per share. B. Riley also issued estimates for Abacus Life’s Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.27 EPS, Q4 2025 earnings at $0.27 EPS, FY2025 earnings at $1.05 EPS, Q1 2026 earnings at $0.36 EPS, Q2 2026 earnings at $0.38 EPS, Q3 2026 earnings at $0.40 EPS and FY2026 earnings at $1.56 EPS.

A number of other research analysts also recently commented on ABL. TD Cowen initiated coverage on shares of Abacus Life in a research report on Wednesday, August 7th. They set a “buy” rating and a $14.00 target price on the stock. Northland Securities started coverage on shares of Abacus Life in a research report on Thursday, October 24th. They set an “outperform” rating and a $13.50 target price on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $13.00 price objective (up previously from $12.00) on shares of Abacus Life in a research report on Friday, November 8th. B. Riley Financial reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Abacus Life in a research report on Friday, August 30th. Finally, Northland Capmk raised shares of Abacus Life to a “strong-buy” rating in a research report on Thursday, October 24th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $14.70.

Abacus Life Price Performance

Abacus Life stock opened at $8.08 on Wednesday. The firm has a 50-day moving average price of $9.17 and a 200-day moving average price of $9.74. The firm has a market capitalization of $603.17 million, a PE ratio of -44.89 and a beta of 0.15. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.65. Abacus Life has a 12-month low of $6.56 and a 12-month high of $13.25.

Abacus Life (NASDAQ:ABL) last posted its earnings results on Thursday, November 7th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.06. Abacus Life had a negative net margin of 11.65% and a positive return on equity of 12.88%. The company had revenue of $28.15 million during the quarter, compared to analysts’ expectations of $26.08 million. During the same period last year, the company posted $0.01 earnings per share.

Institutional Trading of Abacus Life

Hedge funds have recently added to or reduced their stakes in the company. Evernest Financial Advisors LLC purchased a new position in shares of Abacus Life during the 3rd quarter worth approximately $681,000. Principal Financial Group Inc. grew its stake in shares of Abacus Life by 7.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,011,143 shares of the company’s stock worth $10,233,000 after purchasing an additional 74,172 shares during the period. Mendon Capital Advisors Corp purchased a new position in shares of Abacus Life in the 2nd quarter valued at about $4,974,000. Clearbridge Investments LLC acquired a new stake in shares of Abacus Life in the second quarter valued at about $4,342,000. Finally, Royce & Associates LP boosted its holdings in Abacus Life by 35.0% during the third quarter. Royce & Associates LP now owns 297,000 shares of the company’s stock worth $3,006,000 after buying an additional 77,000 shares in the last quarter.

Insiders Place Their Bets

In related news, Director Adam Samuel Gusky bought 18,241 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were bought at an average price of $7.54 per share, with a total value of $137,537.14. Following the completion of the transaction, the director now directly owns 40,959 shares of the company’s stock, valued at $308,830.86. This represents a 80.29 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Matthew Ganovsky sold 156,250 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $8.00, for a total transaction of $1,250,000.00. Following the sale, the insider now directly owns 10,847,047 shares in the company, valued at $86,776,376. This represents a 1.42 % decrease in their position. The disclosure for this sale can be found here. 79.20% of the stock is currently owned by company insiders.

Abacus Life Company Profile

Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.